Fujiwara Yukio, Kiyota Naoko, Hori Masaharu, Matsushita Sayaka, Iijima Yoko, Aoki Koh, Shibata Daisuke, Takeya Motohiro, Ikeda Tsuyoshi, Nohara Toshihiro, Nagai Ryoji
Department of Medical Biochemistry, Faculty of Medical and Pharmaceutical Sciences, Kumamoto University, Honjo, 1-1-1, Kumamoto 860-8556, Japan.
Arterioscler Thromb Vasc Biol. 2007 Nov;27(11):2400-6. doi: 10.1161/ATVBAHA.107.147405. Epub 2007 Sep 13.
We recently identified esculeoside A, a new spirosolane-type glycoside, with a content in tomatoes that is 4-fold higher than that of lycopene. In the present study, we examined the effects of esculeoside A and esculeogenin A, a new aglycon of esculeoside A, on foam cell formation in vitro and atherogenesis in apoE-deficient mice.
Esculeogenin A significantly inhibited the accumulation of cholesterol ester (CE) induced by acetylated low density lipoprotein (acetyl-LDL) in human monocyte-derived macrophages (HMDM) in a dose-dependent manner without inhibiting triglyceride accumulation, however, it did not inhibit the association of acetyl-LDL to the cells. Esculeogenin A also inhibited CE formation in Chinese hamster ovary cells overexpressing acyl-coenzymeA (CoA): cholesterol acyl-transferase (ACAT)-1 or ACAT-2, suggesting that esculeogenin A suppresses the activity of both ACAT-1 and ACAT-2. Furthermore, esculeogenin A prevented the expression of ACAT-1 protein, whereas that of SR-A and SR-BI was not suppressed. Oral administration of esculeoside A to apoE-deficient mice significantly reduced the levels of serum cholesterol, triglycerides, LDL-cholesterol, and the areas of atherosclerotic lesions without any detectable side effects.
Our study provides the first evidence that purified esculeogenin A significantly suppresses the activity of ACAT protein and leads to reduction of atherogenesis.
我们最近鉴定出了一种新的螺旋甾烷型糖苷——番茄苷A,其在番茄中的含量比番茄红素高4倍。在本研究中,我们检测了番茄苷A及其新苷元番茄苷元A对体外泡沫细胞形成以及载脂蛋白E缺陷小鼠动脉粥样硬化形成的影响。
番茄苷元A以剂量依赖的方式显著抑制了人单核细胞衍生巨噬细胞(HMDM)中乙酰化低密度脂蛋白(乙酰-LDL)诱导的胆固醇酯(CE)积累,而不抑制甘油三酯积累,然而,它并不抑制乙酰-LDL与细胞的结合。番茄苷元A还抑制了过表达酰基辅酶A(CoA):胆固醇酰基转移酶(ACAT)-1或ACAT-2的中国仓鼠卵巢细胞中的CE形成,这表明番茄苷元A抑制了ACAT-1和ACAT-2的活性。此外,番茄苷元A阻止了ACAT-1蛋白的表达,而SR-A和SR-BI的表达未受抑制。给载脂蛋白E缺陷小鼠口服番茄苷A可显著降低血清胆固醇、甘油三酯、低密度脂蛋白胆固醇水平以及动脉粥样硬化病变面积,且无任何可检测到的副作用。
我们的研究首次证明,纯化的番茄苷元A可显著抑制ACAT蛋白的活性并减少动脉粥样硬化的发生。